abrdn plc Acquires New Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

abrdn plc acquired a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 64,072 shares of the company's stock, valued at approximately $3,430,000. abrdn plc owned approximately 0.12% of Janux Therapeutics at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Plato Investment Management Ltd raised its stake in Janux Therapeutics by 18.7% in the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company's stock valued at $54,000 after buying an additional 187 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock valued at $87,000 after acquiring an additional 339 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Janux Therapeutics by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock valued at $596,000 after acquiring an additional 1,095 shares during the last quarter. Virtu Financial LLC raised its position in shares of Janux Therapeutics by 48.0% during the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company's stock worth $339,000 after acquiring an additional 2,419 shares in the last quarter. Finally, Avanza Fonder AB purchased a new stake in Janux Therapeutics during the fourth quarter worth approximately $139,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JANX has been the topic of several recent analyst reports. Lifesci Capital upgraded shares of Janux Therapeutics to a "strong-buy" rating in a research note on Friday, December 27th. Leerink Partners increased their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an "outperform" rating in a research report on Tuesday, December 3rd. Stifel Nicolaus boosted their price target on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a "buy" rating in a research report on Tuesday, December 3rd. HC Wainwright raised their price objective on Janux Therapeutics from $63.00 to $70.00 and gave the stock a "buy" rating in a report on Tuesday, December 3rd. Finally, Scotiabank lifted their target price on Janux Therapeutics from $42.00 to $62.00 and gave the stock a "sector perform" rating in a research report on Wednesday, December 4th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $89.90.

Janux Therapeutics Stock Up 1.1 %

JANX traded up $0.39 on Thursday, hitting $37.17. 605,425 shares of the company traded hands, compared to its average volume of 1,082,142. The company has a 50 day moving average of $49.36 and a 200-day moving average of $48.07. Janux Therapeutics, Inc. has a 12-month low of $7.90 and a 12-month high of $71.71. The stock has a market capitalization of $1.95 billion, a PE ratio of -31.77 and a beta of 3.16.

Insider Transactions at Janux Therapeutics

In other news, CEO David Alan Campbell sold 15,000 shares of the business's stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $67.00, for a total transaction of $1,005,000.00. Following the transaction, the chief executive officer now directly owns 242,054 shares in the company, valued at $16,217,618. The trade was a 5.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Andrew Hollman Meyer sold 13,334 shares of the firm's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the sale, the insider now owns 82,139 shares of the company's stock, valued at approximately $4,507,788.32. The trade was a 13.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 86,668 shares of company stock worth $4,872,515 over the last 90 days. 29.40% of the stock is currently owned by insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.